



EP PerMed

European Partnership
for **Personalised Medicine**

EP PerMed

Fast Track Call

20 January 2026



EP PerMed
European Partnership
for **Personalised Medicine**

Agenda

- 01** Introduction and Opening Statement
- 02** Personalised Medicine
- 03** Fast Track Call & Use Cases
- 04** Fast Track 2025
- 05** Wrap up and Closing





EP PerMed

European Partnership
for **Personalised Medicine**

House Keeping Rules

- Please use the Q&A section to ask questions
- Keep your mike off
- The slides and the recording will be shared in the EP Permed Website





EP PerMed

European Partnership
for Personalised Medicine

Opening Statement

Ilias El Houari, PhD

Policy Adviser, Government of Flanders;

EP PerMed Work Package Lead



European Partnership for Personalised Medicine, **EP PerMed**



EP PerMed: Calls and Activities Overview


Personalised Medicine (PM) Calls

Networking Support Call Up to €30,000 to organise a single transnational event focused on translational aspects of PM.
Joint Transnational Call Joint funding of multinational research projects in PM bringing together academic, clinical/public health and private research teams.
Fast-Track Validation Call Up to €80,000 per project to support six-month validation studies.
Research, Innovation and Technology Call Brings together enterprises and clinical actors to test innovative solutions in controlled real-world settings.
Twinning Call Collaboration and knowledge exchange between public administrations through peer-to-peer exchanges.

PM Activities

Venture Creator Programme Guidance by experienced mentors to startups.
Hackathon Young researchers and entrepreneurs tackle common challenges in PM
EP PerMed Connect Event Brings together end-users and innovators to facilitate co-creation.

Innovation Cycle Readiness Levels (RLs)



Useful Resources



Strategic Research & Innovation Agenda for Personalised Medicine

PM research and Innovation activities, challenges

<https://www.eppermed.eu/wp-content/uploads/2023/09/EPPERMed-SRIA.pdf>



EP PerMed Database for Projects in Personalised Medicine Research and Innovation.

57 transnational research and innovation projects funded by EP PerMed

111 projects funded by its predecessor ERA PerMed.

<https://www.eppermed.eu/funding-projects/projects-results/project-database/>

For More Information

Website: [**www.eppermed.eu**](http://www.eppermed.eu)

Mail: [**eppermed@dlr.de**](mailto:eppermed@dlr.de)

LinkedIn: **EP PerMed - the European Partnership for Personalised Medicine**




EP PerMed
European Partnership
for **Personalised Medicine**



EP PerMed
European Partnership
for **Personalised Medicine**

Personalised Medicine



What is Personalised Medicine

EP PerMed adheres to the definition stated in the PerMed SRIA: 'Shaping Europe's Vision for Personalised Medicine' (2015), adopted from the Horizon2020 Advisory Group:

*"Personalised Medicine refers to a medical model using **characterisation of individuals' phenotypes and genotypes** (e.g., molecular profiling, medical imaging, lifestyle data) for tailoring the right **therapeutic strategy** for the right person at the right time, and/or to determine the **predisposition to disease** and/or to **deliver timely and targeted prevention.**"*

Some additional information can be found in the 2018–2020 Advice of the Horizon 2020 Advisory Group for Societal Challenge 1, "Health, Demographic Change and Well-being":

*"Different synonymous terms have been used alongside 'personalised medicine', most commonly 'precision medicine' and **'stratified medicine'**. While there may be subtle differences in the literal meanings of these terms, they usually refer to the same concept when applied in practice. Stratified medicine (mainly used in the UK) is more treatment-dependent, while precision medicine (mostly used in US) has a relatively broad meaning as it refers to 4P (predictive, preventive, personalised and participatory) medicine. We use the term personalised medicine because this term best reflects the ultimate **goal of effectively tailoring treatment based on an individual's 'personal profile', as determined by the individual's genotype and phenotype data.** Based on individuals' profiles, PM aims to identify the optimal treatment regime by avoiding the treatment-failure approach commonly used in current evidence-based medicine."*



EP PerMed

European Partnership
for **Personalised Medicine**



EP PerMed
European Partnership
for **Personalised Medicine**

Fast Track Call



Fast Track - Snapshot

Who can Apply

- Start-up or a team/researcher affiliated with an academic or healthcare research organization.
- Solutions must be at least at proof-of-concept stage (TRL3).



Key Dates

- Call Opens: 02 December 2025.
- Submission Deadline: 10 March 2026.

Funding & Support

- Up to €80,000 per project for validation services. **(5 Selected start-ups)**
- Collaboration with top-tier validation centres.



Expected Outcomes

Projects gain critical evidence, improve TRL levels, and advance towards commercialisation.

Fast Track - Programm Overview

Funding: €80,000 per project as Lump Sum Funding

Funding distribution: at least 70% of funding is to go to the validation centre

Contract: Trilateral agreement with EP PerMed, applicant, and the validation centre

Apply

Applicants submit their proposals through the call application platform.

Selection

EP PerMed, with the help of external evaluators, will evaluate applications and invite the top ten applications to the next stage

Project Plan

If selected, the applicant and their validation centre of choice will be invited to create a detailed project plan of their validation study.

Funding Decision

Five out of the ten applicants will be selected and move to the contracting phase. The funding will be disbursed upon signature of all agreements.

Project Implementation

The six-month joint validation study is conducted in line with the project plan and budget.

Final Report

The applicant, together with the validation centre, will submit a final report on the validation study at the end of the project to receive the final tranche of funding.

Fast Track Stage 1 – Eligibility and Submission Process



<https://apply.eithealth.eu/>



Submission in English and before the Deadline



Applications can be submitted by a start-up or a team/ researcher affiliated with an academic or healthcare research organization. The solution must be at least TRL 3 or more.



The proposed solution must align with the definition of Personalised Medicine (PM) as outlined in the call document.



Registered in an EU Member State or a Horizon Europe-associated country

Registration Options

Thank you for your interest in EIT Health opportunities.

To register, please read through the options below. After you select the one that best describes you, we will ask you a few questions to learn more about you and/or your company. When you finish inputting your information, please look for an email from us to confirm your registration. Please note that the information you share with us here will transfer over to your application of choice.

Please select the option below that best describes you:

Individual - Expert

Please select this option if you are looking to apply to our **Call for Experts**, and you are **not** applying as part of a start-up or an organisation.

Individual - Student

Please select this option if you are looking to apply to our **Education Programmes**, and you are **not** applying as part of a start-up or an organisation.

If you are applying to one of our **i-Days** event, please choose this registration option.

Representative of an organisation (excludes start-ups)

Please select this option if you wish to apply as a representative of an organisation, such as industry, academia, research, hospitals, NGOs, cluster organisations, cities or municipalities. This option includes EIT Health Partners or Members (e.g., Core Partners, Associate Partners, and affiliated entities of both) and organisations that are new to the EIT Health Community.

If this option best describes you, you will be able to apply to our **Flagships Calls**. Please note that if you select this option, it may take up to 48 hours for your registration to be approved.

Representative of a start-up or independent team

Please have the information about your start-up/team at hand as you will need it to register in the system. If you are part of a start-up venture / team, you will be able to apply to EIT Health acceleration programmes and the **Flagships Calls**.

Fast Track Stage 1 – Eligibility and Submission Process



<https://apply.eithealth.eu/>



Submission in English and before the Deadline



Applications can be submitted by a start-up or a team/ researcher affiliated with an academic or healthcare research organization. The solution must be at least TRL 3 or more.




The proposed solution must align with the definition of Personalised Medicine (PM) as outlined in the call document.



Registered in an EU Member State or a Horizon Europe-associated country

#	Programme	Programme Category	Additional Information	Close Date (time in CET)	
1	Call for Experts	Other		19/03/2027 00:00	Your organisation type is not eligible
2	EPPermed: Twinning Call (EPTwin)	Flagship and Consortium Calls	Advancing Collaborative Implementation of Personalised Medicine Approaches in Healthcare	26/02/2026 16:00	more info Apply Now
3	EP PerMed: Fast Track (EPFT)	Flagship and Consortium Calls	EP PerMed - Fast Track Call 2026	10/03/2026 16:00	more info Apply Now
4	Value-based Healthcare Pioneer (VBHCP)	Education Programme		31/12/2026 23:59	Your organisation type is not eligible
5	Health Entrepreneurship 101 (HE101)	Education Programme		31/12/2026 23:59	Your organisation type is not eligible
6	Unlocking Health Data: Navigating Biobanks for European Collaboration (NBC)	Education Programme		31/12/2026 23:59	Your organisation type is not eligible
7	Data Entrepreneurs: A course for professionals (DE)	Education Programme		31/12/2026 23:59	Your organisation type is not eligible
8	Foundations of Design Thinking in Healthcare (FDTH)	Education Programme		31/12/2026 23:59	Your organisation type is not eligible

Fast Track - Timeline



Fast Track – Evaluation

Activity excellence and strategic fit

Implementation and Feasibility

Impact and sustainability

**Implementation and Feasibility of the
Project Plan**

Lump Sum Budget Excel

Ethical, Legal, and Social Issues (ELSI) Review

- **Stage One – Initial Application:** submitted directly by the applicant through the call application platform. This stage score will represent 70% of the total final score.
- **Stage Two – Project Plan and Budget:** Stage One applications that are positively assessed will be invited to develop a project and budget plan jointly between the applicant and their selected Validation Centre and submit it through the same call application platform. This stage score will represent 30% of the total final score.

Fast Track – Programme Admission

Activity excellence and strategic fit

Implementation and Feasibility

Impact and sustainability

**Implementation and Feasibility of the
Project Plan**

Lump Sum Budget Excel

Ethical, Legal, and Social Issues (ELSI) Review

- Top **10 preselected applicants** will be invited to provide a detailed validation plan, including detailed cost plan.
- If the study plan foresees ethical approval, it must be submitted to the respective Ethical Board(s). A copy of the application should also be provided before the validation starts.
- Both start-up and validation centers have signed the three-party Financial Support Agreement (between EIT Health as funder, the validation centre, and the PM solution owner/applicant).

Fast Track – Funding and Grant Payout

- **Top 5 selected** projects that successfully submitted their project plan and concluded a contract with a chosen validation centre will receive funding of up to 80,000 EUR per project
- This funding is intended to cover validation services and **eligible costs**
- At least 70% of the budget allocated specifically to validation services.
- The payment will be distributed in two instalments: an initial pre-payment of 50% of the total funding will be made at the start of the project. The remaining 50% will be disbursed upon approval of the final activity report.

Amount to be paid	Description	Payment tranche
50 % of the Lump Sum Contribution	Validation Centre 35% of the total funding awarded. Start-Up 15% of the total funding awarded.	Pre-financing
50 % of the Lump Sum Contribution	Validation Centre 35% of the total funding awarded. Start-Up 15% of the total funding awarded.	Final payment

Fast Track – Validation Centers



- The evaluation of validation centers is conducted during the second stage, as ensuring a good fit between the services provided by the center and the specific needs of the start-up is a crucial part of the evaluation process.
- The validation center and the start-up (or research team) must belong to different institutes or organizations; they cannot be part of the same entity
- In case applicants struggles to find a suitable validation center during the stage 2 process, the programme coordination team can support in the matchmaking process by providing suggestion through the EP Permed Network.
- Stage Two applications (project plan and project budget) must be submitted by an incorporated start-up or a team affiliated with an academic or healthcare research organization and a validation centre that is legally registered in an EU Member State or a Horizon Europe associated Country. A list of Horizon Europe Associated countries is available [here](#).

Fast Track – Potential List of Validation centers



- [EITH database of biobanks and health registers https://biobankshealthdata.eithealth.eu/](https://biobankshealthdata.eithealth.eu/)

→ Accelerate your business using European biobanks and health data registries. Learn how to find and access the samples and data you need. Welcome to explore the biobanks and registries in our database

- [Database of European biological and biomedical imaging: https://www.eurobioimaging.eu/validation/](https://www.eurobioimaging.eu/validation/)

→ 18 Member countries + the European Molecular Biology Laboratory (EMBL), 41 National Nodes (**19 Nodes offers preclinical or in vivo imaging technologies, 11 offers clinical imaging, 8 specialising in medical data analysis**), 237 facilities across Europe, 120+ state-of-the-art imaging technologies.

- [BBMRI database of samples and data in biobanks](#)

- [ERIC Forum](#)



EP PerMed

European Partnership
for Personalised Medicine



EP PerMed
European Partnership
for Personalised Medicine

Use Cases



Biobank as validation center

Current status: Start-up has designed algorithm to estimate the genetic risk of colorectal cancer among healthy persons. The algorithm was established as a result of research project using national e-health database and genetic profiles available in one country.

Aim of the validation: to validate the algorithm based in other population using biobank data: 1) genetic information, 2) e-health data

Important to take into account:

- NB! Validation foresee ethical approval, that should be in place for the beginning of the project
- As Fast Track validation is 6 month long project with budget 80K € - the access to “ready-to-use data” is optimal instead of asking **samples** from biobank
- Biobank should have **broad consent** to provide health data and genetic data
- Biobank should have right to provide data (samples) for **commercial use**
- Additional partner might be needed for bioinformatics services

Bioimage database as validation center



Current status: Research team has designed algorithm to provide accurate diagnostics based on combination of the molecular profile and medical images.

Aim of the validation: The algorithm needs to be validated further using Euro Bioimaging database.

Important to take into account:

- NB! Validation might foresee ethical approval, that should be in place for the beginning of the project
- Additional partner might be needed for image analysis services

Living lab as validation center

Current status: Start-up has developed several PM tools for early diagnostics of mental diseases and disease (subtype) identifications.

Aim of the validation: Feedback to the results communication tool

- Validation in real-life test and experimentation environment
- Feedback from end users after testing in multi-stakeholder environment (incl. by patients and medical doctors).
- Co-creation of user-friendly interface in 3 language.

Important to take into account:

- Impact of the study is crucial

Fast Track 2025 Overview



Fast Track 2025 – Testimonials



Altogether, the EP PerMed Fast Track programme indeed lived up to the expectation to quickly advance the TRL and MRL of our technology, as in just 6 months we could validated both the market potential and efficacy of the therapy.

Firstly, we want to express what a pleasure it has been to be part of the EP PerMed initiative. We are grateful to have such an exceptional partner and have greatly enjoyed the collaboration. We are genuinely proud of the progress we have made together so far and are looking forward to the upcoming in vivo readouts.

Wrap-up and Summary



Summary

- Start-up or a team/researcher affiliated with an academic or healthcare research organization with a proof-of-concept at least stage (TRL3).
- Application form is open in smart Simple. [Apply here.](#)

- Deadline is on the **10 of March 2026**
- In case your solution is very early, you can check out other open calls within the EP Permed project.



Thank You



EP PerMed Accelerator Calls

E: calls_eppermed@eithealth.eu

<https://www.eppermed.eu/>

Question?

